Immunosuppressive treatment of HBsAg‐positive chronic liver disease: Significance of HBeAg
Ulrik Tage‐Jensen, Jan Aldershvile, Poul Schlichting, The Copenhagen Study Group Liver Disease – 1 January 1985 – In a randomized clinical trial in 148 patients of azathioprine vs. prednisone treatment of chronic aggressive hepatitis and/or nonalcoholic cirrhosis, 20 were HBsAg positive on entry. In this subgroup sequential serum samples were investigated for HBs and HBe markers by radioimmunoassay. At the time of evaluation, 13 patients were still alive; their median age was 53 years (25 to 72) and median follow‐up time was 46 months (23 to 82).